The list price of Humulin-a short-acting human regular insulin-will be cut by 70% beginning in Q4 2023. This price reduction most significantly helps those facing the full list price of Humalog-those who don’t have or are unable to get health insurance. Vials will be between $82-$86 while a five-pack of pens is expected to cost $92.Īctual out-of-pocket costs will be based on insurance coverage and participation in the $35 copay cap at participating pharmacies or through the Lilly Insulin Value Program savings card. The list price of Humalog-rapid-acting insulin lispro, the most commonly prescribed Lilly insulin-will be cut by 70% beginning in Q4 2023. Insulin pricing advocates have called for significant list price reductions as a primary measure needed to address the U.S. It is not a biosimilar but is the same exact medication without the Humalog branding. Insulin Lispro is non-branded Humalog, Lilly’s brand of rapid-acting insulin. Starting May 1, the list price of one vial of Insulin Lispro Injection 100 units/mL will be $25. This list price is a 78% discount compared to Lantus. ![]() Rezvoglar is basal insulin glargine-aglr, which is biosimilar to and interchangeable with Lantus®, basal insulin glargine. Starting April 1, the list price of a five-pack of RezvoglarTM KwikPens® will be $92. Learn more about the program here and about Medicare coverage for diabetes here. People covered under Medicare can sign up for specific coverage plans that cap out-of-pocket insulin costs at $35. You can go to to immediately download the pharmacy card. This savings card will also work for those with commercial insurance who use retail pharmacies not participating in the automatic out-of-pocket cap. This process removes the step of downloading Lilly’s existing $35 copay card for those with commercial insurance.Īvailable since April 2020, people with no health insurance coverage can use the Lilly Insulin Value Program savings card to cap out-of-pocket costs at $35 per month per type of insulin. There is no limit to the number of vials or pens that can be covered each month as long as they are prescribed, but there is a $16,000 annual coverage limit. Starting now for people with commercial insurance, Lilly will automatically cap out-of-pocket insulin costs at $35 per month per type of insulin at participating retail pharmacies. ![]() These measures build upon Lilly’s $35 copay program (initially launched in April 2020) and include the May 1 launch of Insulin Lispro (non-branded Humalog®) at a $25 per vial list price, as well as future list price reductions for Humalog and Humulin® insulins. On March 1, 2023, Lilly announced insulin list price and out-of-pocket cost reductions in the United States. If you or a loved one are struggling to afford or access insulin, you can find which cost-saving tools you may qualify for through our tool. Editor’s Note: People who take insulin require consistently affordable and predictable sources of insulin at all times.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |